Novel prostate cancer screening technology targeting commercialization in 2017
Verification of test accuracy and reliability for CLIA lab access
SYDNEY--(BUSINESS WIRE)--Minomic International Ltd, an Australian immuno-oncology company, has initiated a prospective US trial of its MiCheck® prostate cancer screening test. This important trial will further verify MiCheck’s accuracy and reliability in detecting prostate cancer, especially for identifying patients with clinically significant cancer. MiCheck® technology is a blood based multi-index analyte assay capable of identifying the presence of prostate cancer.
Minomic International Ltd
Brad Walsh, Ph.D., +61 413-231-296
Chief Executive Officer